Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)

from the beginning

Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L, FCF

• OP Variance Analysis (Q3): Higher sales driven by continued demand

• OP Variance Analysis (Q3 YTD): Contribution from pricing measures and strong sales

• Revenue by Region: Steady progress globally, driven by US and Europe

• C&V: Global sales and profit exceeded planned figures, driven by US

• TMCS: Revenues and profits increased due to strong sales including one-time factors and the effects of pricing measures

• TBCT: Both sales and income increased due to accelerated development of the plasma innovation business

Reference

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and Amortization, R&D Expenses

• Cash Flow (Q3 YTD)

• Cash Flow (Q3)

• Free Cash Flow：93.9 B JPY（YoY +55.8 B JPY）

• Foreign Exchange Sensitivity

@